Literature DB >> 19483156

A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.

Carlos A Scrideli1, Juliana G Assumpção, Mônica A Ganazza, Marcela Araújo, Silvia R Toledo, Maria Lúcia M Lee, Elisabete Delbuono, Antonio S Petrilli, Rosane P Queiróz, Andrea Biondi, Marcos B Viana, José A Yunes, Silvia R Brandalise, Luiz G Tone.   

Abstract

BACKGROUND: Minimal residual disease is an important independent prognostic factor in childhood acute lymphoblastic leukemia. The classical detection methods such as multiparameter flow cytometry and real-time quantitative polymerase chain reaction analysis are expensive, time-consuming and complex, and require considerable technical expertise. DESIGN AND METHODS: We analyzed 229 consecutive children with acute lymphoblastic leukemia treated according to the GBTLI-99 protocol at three different Brazilian centers. Minimal residual disease was analyzed in bone marrow samples at diagnosis and on days 14 and 28 by conventional homo/heteroduplex polymerase chain reaction using a simplified approach with consensus primers for IG and TCR gene rearrangements.
RESULTS: At least one marker was detected by polymerase chain reaction in 96.4% of the patients. By combining the minimal residual disease results obtained on days 14 and 28, three different prognostic groups were identified: minimal residual disease negative on days 14 and 28, positive on day 14/negative on day 28, and positive on both. Five-year event-free survival rates were 85%, 75.6%, and 27.8%, respectively (p<0.0001). The same pattern of stratification held true for the group of intensively treated children. When analyzed in other subgroups of patients such as those at standard and high risk at diagnosis, those with positive B-derived CD10, patients positive for the TEL/AML1 transcript, and patients in morphological remission on a day 28 marrow, the event-free survival rate was found to be significantly lower in patients with positive minimal residual disease on day 28. Multivariate analysis demonstrated that the detection of minimal residual disease on day 28 is the most significant prognostic factor.
CONCLUSIONS: This simplified strategy for detection of minimal residual disease was feasible, reproducible, cheaper and simpler when compared with other methods, and allowed powerful discrimination between children with acute lymphoblastic leukemia with a good and poor outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19483156      PMCID: PMC2688569          DOI: 10.3324/haematol.2008.003137

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  44 in total

1.  Duplex PCR facilitates the identification of immunoglobulin kappa (IGK) gene rearrangements in acute lymphoblastic leukemia.

Authors:  M Nakao; J W Janssen; C R Bartram
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

2.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.

Authors:  T Flohr; A Schrauder; G Cazzaniga; R Panzer-Grümayer; V van der Velden; S Fischer; M Stanulla; G Basso; F K Niggli; B W Schäfer; R Sutton; R Koehler; M Zimmermann; M G Valsecchi; H Gadner; G Masera; M Schrappe; J J M van Dongen; A Biondi; C R Bartram
Journal:  Leukemia       Date:  2008-01-31       Impact factor: 11.528

3.  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.

Authors:  E R Panzer-Grümayer; M Schneider; S Panzer; K Fasching; H Gadner
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

4.  BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL).

Authors:  A Porwit-MacDonald; E Björklund; P Lucio; E G van Lochem; J Mazur; A Parreira; M W van den Beemd; E R van Wering; E Baars; G Gaipa; A Biondi; J Ciudad; J J van Dongen; J F San Miguel; A Orfao
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

Review 5.  Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?

Authors:  T Szczepański
Journal:  Leukemia       Date:  2007-02-15       Impact factor: 11.528

6.  Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.

Authors:  J W Donovan; M Ladetto; G Zou; D Neuberg; C Poor; D Bowers; J G Gribben
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

Review 7.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.

Authors:  J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

8.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

Review 9.  Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.

Authors:  Martin Stanulla; Gunnar Cario; Barbara Meissner; André Schrauder; Anja Möricke; Hansjörg Riehm; Martin Schrappe
Journal:  Blood Cells Mol Dis       Date:  2007-05-25       Impact factor: 3.039

10.  Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

Authors:  E Fronkova; E Mejstrikova; S Avigad; K W Chik; L Castillo; S Manor; L Reznickova; T Valova; K Zdrahalova; O Hrusak; Y Jabali; M Schrappe; V Conter; S Izraeli; C K Li; B Stark; J Stary; J Trka
Journal:  Leukemia       Date:  2008-02-28       Impact factor: 11.528

View more
  17 in total

1.  Monoclonal B-cell lymphocytosis (MBL, CD4+/CD8 weak T-cell large granular lymphocytic leukemia (T-LGL leukemia) and monoclonal gammopathy of unknown significance (MGUS): molecular and flow cytometry characterization of three concomitant hematological disorders.

Authors:  Daniel Mazza Matos; Ana Cesarina Vitoriano de Oliveira; Maria de Nazaré Amaral Tomé; Carlos Alberto Scrideli
Journal:  Med Oncol       Date:  2012-06-12       Impact factor: 3.064

2.  Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia.

Authors:  Martin Stanulla; André Schrauder
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  Prospective evaluation of HSV, Candida spp., and oral bacteria on the severity of oral mucositis in pediatric acute lymphoblastic leukemia.

Authors:  Regina Maria Holanda de Mendonça; Marcela de Araújo; Carlos Emilio Levy; Joseane Morari; Rosângela A Silva; José Andres Yunes; Silvia Regina Brandalise
Journal:  Support Care Cancer       Date:  2011-05-20       Impact factor: 3.603

4.  Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP.

Authors:  Daniel Antunes Moreno; Howard Lopes Ribeiro Junior; Angelo Brunelli Albertoni Laranjeira; Gustavo Alencastro Veiga Cruzeiro; Kleiton Silva Borges; Karina Bezerra Salomão; Fernando Silva Ramalho; José Andres Yunes; Cleide Lúcia Araújo Silva; Eduardo Magalhães Rego; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

5.  Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia.

Authors:  Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Maria Lucia de Martino Lee; Antonio Ramos Calixto; Bruno Geloneze; Marise Lazaretti-Castro; Gil Guerra-Junior
Journal:  J Bone Miner Metab       Date:  2015-12-11       Impact factor: 2.626

6.  Cranial radiotherapy predisposes to abdominal adiposity in survivors of childhood acute lymphocytic leukemia.

Authors:  Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Maria Lúcia de Martino Lee; Solange Andreoni; Bruno Geloneze; Henrique Lederman; Gil Guerra-Junior
Journal:  Radiat Oncol       Date:  2013-02-21       Impact factor: 3.481

7.  Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia.

Authors:  Kyung Nam Koh; Meerim Park; Bo Eun Kim; Ho Joon Im; Chan-Jeoung Park; Seongsoo Jang; Hyun Sook Chi; Jong Jin Seo
Journal:  Korean J Pediatr       Date:  2010-11-30

8.  Subcutaneous adipose tissue plays a beneficial effect on subclinical atherosclerosis in young survivors of acute lymphocytic leukemia.

Authors:  Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Maria Lucia de Martino Lee; Carlos Manoel de Castro Monteiro; Antonio Carlos de Camargo Carvalho; Antonio Ramos Calixto; Bruno Geloneze; Gil Guerra-Junior
Journal:  Vasc Health Risk Manag       Date:  2015-08-18

9.  Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia.

Authors:  Hamilton L Gimenes-Teixeira; Antonio R Lucena-Araujo; Guilherme A Dos Santos; Dalila L Zanette; Priscila S Scheucher; Luciana C Oliveira; Leandro F Dalmazzo; Wilson A Silva-Júnior; Roberto P Falcão; Eduardo M Rego
Journal:  Exp Hematol Oncol       Date:  2013-04-08

10.  Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia.

Authors:  Lucila H Oliveira; Josiane L Schiavinato; Mariane S Fráguas; Antonio R Lucena-Araujo; Rodrigo Haddad; Amélia G Araújo; Leandro F Dalmazzo; Eduardo M Rego; Dimas T Covas; Marco A Zago; Rodrigo A Panepucci
Journal:  Cancer Sci       Date:  2015-09-21       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.